FDA accepts Connetics Corp. NDA filing for Extina

Article

Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.

Related Videos
Related Content

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook

October 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.